An observational study in Healthy Pregnant Women, Obese Pregnant Women and Gestational Diabetes, sponsored by Medical University of Graz. Recruiting at 1 site in Austria. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Medical University of Graz · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes, Gestational with a site in Austria — 4 open to participants now, 5 under way, none of them phase 3. Diabetes, Gestational · Austria.
Among the 11 studies in Diabetes, Gestational with a site in Austria, this one is one of 2 that started in 2023, is one of 6 observational ones, and was the 8th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →4 of the 11 studies in Diabetes, Gestational with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–45 · Women only
Medical University of Graz · Sites in Austria
Ages 18+ · Women only
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche · Sites in Austria, Italy
Ages 35+ · Women only
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 175 across 290 observational studies indexed under Diabetes, Gestational.
Median enrollment 67 across the 5 interventional studies, 275 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 3 most frequent:
Medical University of Graz is the lead sponsor of 471 studies on the registry; 98 are open to participants now.
Medical University of Graz has 3 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
1 of the studies in Diabetes, Gestational with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07685015Medical University of ViennaThe Impact of Myo-Inositol on Glycemic Control and Oxidative Stress in Gestational Diabetes Mellitus | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Diabetes, Gestational with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational cohort study is to gain deep insights into how metabolic disorders such as obesity or diabetes during pregnancy affect the metabolic and cardiovascular health of mother and child in the short and long term.
It will investigate the following questions:
Pregnancy is a sensitive and determining period in life where maternal and environmental cues can influence mother and offspring health short and long term. Negative exposures in pregnancy can have long term consequences, such as higher risk for development or aggravation of obesity, metabolic and cardiovascular diseases. However, preventive measures such as life style interventions can be particularly effective (window of opportunity) and could mitigate disease trajectories.
During a healthy pregnancy, a multitude of fine-tuned physiological adaptations takes place to meet the demands of the developing fetus and prepare maternal organism for delivery and lactation. These physiological changes affect the maternal metabolism, cardiovascular system, immune system, microbiome, or endocrine system. Unfavorable or adverse maternal factors (e.g. endocrine, genetic, metabolic, lifestyle factors) may compromise these adaptations, promoting pregnancy complications such as gestational diabetes (GDM), hypertensive pregnancy diseases, fetal growth restriction, fetal overgrowth, or preterm birth. These pregnancy pathologies not only pose an immediate health risk to both mother and child, but also may negatively impact the longer-term cardiovascular, endocrine, and metabolic health of both.
Offspring exposed in utero to maternal diabetes, hypertensive diseases or maternal obesity are at higher risk of developing obesity, diabetes of cardiovascular disorders later in life. For the mother, each pregnancy loads a metabolic burden, which is aggravated by pregnancy complications, also increasing the mother's risk of developing metabolic or cardiovascular disease later in life.
Therefore, prediction and risk evaluation, early diagnosis and prognosis, safe (non-invasive) therapeutic strategies are urgently needed to provide intervention as early as possible (pre-conceptional, during pregnancy and postpartum) to avoid potential manifestations of long-term health problems. Due to the relatively short duration of pregnancy and the often increased health awareness of expectant mothers, pregnancy is an ideal phase to identify origins of disease, evaluate personalized diagnostic and predictive markers, as well as preventive strategies.
In the recent years, the concept of deep phenotyping during pregnancy has emerged as a means to tackle the current inadequate understanding on the pathobiology of pregnancy related diseases and heath trajectories.
The proposed pregnancy and birth cohort aims to meet this need providing comprehensive sets of biological samples, clinical data, physical measurements and life style information for deep phenotyping of pregnancy and early life. Special focus will be put on monitoring glucose metabolism throughout pregnancy and postpartum, since the standard care oGTT at 24 to 28 weeks merely detects an already manifest glucose intolerance without giving any information on potentially preconceptionally existing impaired glucose tolerance/pre-diabetes or predicting maternal hyperglycemia thereafter, in late pregnancy.
This study will be a monocentric, prospective cohort with the goal of recruiting 80-100 participants per year. The study will be conducted at the LKH Graz University Hospital, Department of Gynecology and Obstetrics, Outpatient Clinic. Women with child wish will be recruited at the Center for Assisted Reproductive Technologies (Center for Gynecologic Endocrinology and Reproductive Medicine, Kinderwunsch-Zentrum) or pregnant women attending their routine first trimester screening visits will be enrolled and followed throughout their pregnancy until 8-12 weeks postpartum. There will be up to 6 visits: (T0 preconceptional enrollment), T1 (10-14 weeks of gestation, first trimester screening/enrollment), T2 (24-28 weeks of gestation, time of routine care oGTT); T3 (34-37 weeks of gestation, late pregnancy control visit in preparation for delivery), T4 (delivery), T5 (8-12 weeks postpartum; follow-up after pregnancy complications). The study is designed to closely monitor glucose metabolism and requires participants to be fasting for blood sampling. Women will be offered an oGTT at each visit (at T2 standard of care), but may opt out.
The study will collect clinical markers and measurements of metabolic and hemodynamic parameters, as well as a comprehensive collection of biospecimens and metadata on lifestyle factors (nutrition, physical activity). Advanced methods such as maternal and infant air displacement plethysmography (BODPOD /PEAPOD) will provide accurate body composition measurements. Endothelial/vascular function is assessed by hemodynamic parameters, including pulse wave velocity measured with a Vicorder®.
Eligible for participation are women with child wish and women with an on-going pregnancy who are planning to give birth at the university hospital in Graz, Austria. Women will be recruited as soon as possible in their pregnancy, but not after the 14th week of gestation. They will be recruited through the outpatient clinics and, in case of women with child wish, at the center for assisted reproductive technologies at the Department of Obstetrics and Gynecology, at Medical University Graz.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Maternal adiposity
Measured as fat mass and fat-free mass by air displacement plethysmography (via BODPOD) at 10-14 weeks, 20-24 weeks and 34-37 weeks of gestation and 8-12 weeks post partum.
Time frame: From enrolment to 8-12 weeks post partum
Maternal fasting blood glucose
Fasting blood glucose as measured in mg/mL from NaF blood tubes at 10-14 weeks, 24-24 weeks, 34-37 weeks of gestation and 8-12 postpartum.
Time frame: from enrollment to 8-12 weeks postpartum
Maternal blood pressure
Blood pressure will be measured at 10-14 weeks, 24-28 weeks and 34-37 weeks of gestation and 8-12 weeks post partum.
Time frame: From enrolment to 8-12 weeks postpartum
Maternal lipid profiles - triglycerides
Analysis of serum lipid profiles: triglycerides at 3 time points during pregnancy (10-14 weeks (wks); 24-28wks; 34-37wks), and 8-12 wks postpartum.
Time frame: From enrolment to 8-12 weeks post partum
Maternal lipid profiles: phospholipids
Analysis of serum lipid profiles: phospholipids at 3 time points during pregnancy (10-14wks; 24-28wks; 34-37wks), and 8-12wks postpartum.
Time frame: From enrolment to 8-12 weeks post partum
Maternal lipid profiles: free fatty acids
Analysis of serum lipid profiles: free fatty acids at 3 time points during pregnancy (10-14wks; 24-28wks; 34-37wks), and 8-12wks postpartum.
Time frame: From enrolment to 8-12 weeks post partum
Maternal lipid profiles: total cholesterol
Analysis of serum lipid profiles: total cholesterol at 3 time points during pregnancy (10-14wks; 24-28wks; 34-37wks), and 8-12wks postpartum.
Time frame: From enrolment to 8-12 weeks post partum
Maternal lipid profiles: HDL cholesterol
Analysis of serum lipid profiles: HDL cholesterol at 3 time points during pregnancy (10-14wks; 24-28wks; 34-37wks), and 8-12wks postpartum.
Time frame: From enrolment to 8-12 weeks post partum
Maternal lipid profiles: LDL cholesterol
Analysis of serum lipid profiles: LDL cholesterol at 3 time points during pregnancy (10-14wks; 24-28wks; 34-37wks), and 8-12wks postpartum.
Time frame: From enrolment to 8-12 weeks post partum
Maternal endothelial function
measured as pulse wave velocity using a Vicorder®.
Time frame: From enrolment to 8-12 weeks post partum
Maternal cytokine profile
Serum cytokines will be analysed by multiplexing at all visits during pregnancy and postpartum.
Time frame: From enrolment to 8-12 weeks postpartum
Gestational diabetes
assessed through 75g 2h oral glucose tolerance test performed at 24-28 weeks of gestation.
Time frame: From enrolment to child birth; 6 months
Hypertensive disorders of pregnancy
gestational hypertension and preeclampsia, assessed through medical chart review.
Time frame: From enrolment to child birth; 6 months
Neonatal body composition at birth
Measured as fat mass and fat-free mass by air displacement plethysmography (via PEAPOD)
Time frame: between delivery and 48h postpartum
Neonatal C-peptide in cord blood
Concentrations of C-peptide in cord blood
Time frame: at birth
Neonatal cytokine profile
Neonatal inflammatory cytokines will be measured in cord blood serum collected at birth using multiplexing cytokine assays.
Time frame: at birth
Neonatal epigenetic profile
Epigenomic profile of the umbilical cord blood measured by DNA methylation
Time frame: at birth
Human milk oligosaccharide (HMO) profile in maternal blood
HMOs will be analysed in maternal serum by high pressure liquid chromatography (HPLC) with fluorescence detection
Time frame: From enrolment to 8-12 weeks postpartum
Human milk oligosaccharide (HMO) profile in maternal urine
HMOs will be analysed in maternal serum by high pressure liquid chromatography (HPLC) with fluorescence detection
Time frame: From enrolment to 8-12 weeks post partum
Human milk oligosaccharide (HMO) profile in cord blood
HMOs will be analysed in umbilical cord blood serum by high pressure liquid chromatography (HPLC) with fluorescence detection
Time frame: at birth
Human milk oligosaccharide (HMO) profile in breast milk
HMOs will be analysed in breast milk by high pressure liquid chromatography (HPLC) with fluorescence detection
Time frame: from child birth to 8-12 weeks postpartum
Adverse pregnancy outcome
Composite measure including gestational hypertension, preeclampsia, gestational diabetes, preterm delivery, low birth weight, assessed through medical chart review
Time frame: From enrolment to child birth; 6 months
Maternal vaginal microbiome
From the extracted DNA, 16S rRNA genes will be amplified using specific primers for bacterial and archaeal communities. The amplicons obtained will be prepared for Illumina MiSeq Sequencing.
Time frame: From enrolment to 8-12 weeks postpartum
Plan to share: Yes — All IPD underlying results in a publication will be shared.
Supporting information: Study protocol, Informed consent form
Time frame: Data will be made available starting 1 year after publication with no end date.
Access criteria: Data access will be provided to external researchers who submit a methodologically sound proposal for secondary data analysis that is approved by the study investigators and should be submitted to the study PI.
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jun 2033, 119 months after the start.
Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 119 months is above that.
Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.